Alnylam Pharmaceuticals, Inc. vs Merck & Company, Inc. — Stock Comparison
Q·Score Breakdown
8
Bullish
Overall
6.7
Neutral
Quality
Health
Growth
Valuation
Sentiment
ALNY
Consensus analyst target of $449.48 is 52% above current price.
MRK
Forward P/E of 11.5× is low relative to sector peers.
Analyst Consensus
BUY
Target $449.48 (+51.8%)
25 analysts
BUY
Target $129.74 (+15.7%)
27 analysts
Fundamentals
ALNY
MRK
74.6×
Trailing P/E
31.5×
21.2×
Forward P/E
11.5×
12.6%
Profit Margin
13.6%
80.8%
Gross Margin
76.6%
90.4%
ROE
—
96.4%
Revenue Growth
4.9%
—
Earnings Growth
—
0.38
Beta
0.28
—
Price / Book
—
$39.5B
Market Cap
$277.0B
$246 – $496
52-Week Range
$73 – $125
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →